InventionmedWAR:INM +7.77%17 EBITDA Margin % is 103.37% as of Mar. 2026. GuruFocus rates WAR:INM with a GF Score™ of 17/100. The stock has 7 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Inventionmed ranks better than 99.14% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Inventionmed's EBITDA for the
three
months ended in Mar. 2026 was zł0.80 Mil. Inventionmed's Revenue for the
three
months ended in Mar. 2026 was zł0.77 Mil. Therefore, Inventionmed's EBITDA margin for the quarter that ended in Mar. 2026 was 103.37%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Inventionmed EBITDA Margin % Related Terms
Inventionmed EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Inventionmed's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:INM vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Inventionmed's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inventionmed EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inventionmed's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Inventionmed's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inventionmed (WAR:INM) has a EBITDA Margin % of 103.37% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Inventionmed and its competitors. According to the industry distribution chart, Inventionmed ranks #7 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 0.90000000000001%.
Is Inventionmed's EBITDA Margin % too high?
Inventionmed's current EBITDA Margin % is 103.37%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Inventionmed's value of 103.37% is 1283.8% above this industry median. Based on the distribution chart, Inventionmed ranks #7 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Inventionmed has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Inventionmed's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Inventionmed ranks #7 out of 815 companies for EBITDA Margin %. This places Inventionmed in the top 1% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.47. Inventionmed's value of 103.37% is 1283.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inventionmed's current EBITDA Margin % of 103.37% is 1283.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Inventionmed and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inventionmed's current EBITDA Margin % is 103.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventionmed stock overvalued right now?
Inventionmed (WAR:INM) has a current EBITDA Margin % of 103.37%. The current EBITDA Margin % is 103.37% and 1283.8% above the Medical Devices & Instruments industry median of 7.47. Inventionmed's overall GF Score™ is 17/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Inventionmed (WAR:INM), the current EBITDA Margin % is 103.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inventionmed SA focuses on the development of medical simulators based on VR technology for use in education in esthetic and clinical dermatology. The company's project consists of TutorDerm, Double immersion, Virtual Syringe, and others.
17GF Score
Get the complete analysis for WAR:INM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:INM has been successfully added to your 
